Contact Us / Request a Quote Download Manuals
Advanced Cell Diagnostics Advanced Cell Diagnostics

Search form

Please sign in
  • Log In
  • Register
  • How to Order
  • What to Buy
0 My Cart
X

You have no items in your shopping cart.

Menu
X
  • Products +
    RNAscope™/BaseScope™/ miRNAscope™
    +
    • Assay Selection Guide
    Target Probes
    +
    • All About Probes
    • Catalog Probes
    • Probe Sets
    • New Probe Request
    Manual Assays
    +
    RNAscope™ Chromogenic
    • Overview
    • RNAscope™ 2.5 HD Assay-Brown
    • RNAscope™ 2.5 HD Assay-Red
    • RNAscope™ 2.5 HD Duplex Assay
    RNAscope™ Multiplex Fluorescent
    • Overview
    • RNAscope™ HiPlex v2 Assay
    • RNAscope™ Multiplex Fluorescent V2
    BaseScope™
    • Overview
    • BaseScope™ Assay Red
    • BaseScope™ Duplex Assay
    miRNAscope™
    • Overview
    • miRNAscope™ Assay red
    • RNAscope™ Plus smRNA-RNA Assay
    DNAscope™
    • Overview
    • DNAscope™ Duplex Assay
    Automated Assays
    +
    For Lunaphore COMET™
    • RNAscope™ HiPlex Pro for COMET™
    For Leica systems
    • Overview
    • RNAscope™ 2.5 LS Assay-Brown
    • RNAscope™ 2.5 LS Assay-Red
    • RNAscope™ 2.5 LS Duplex Assay
    • RNAscope™ Multiomic LS Assay
    • RNAscope™ 2.5 LS Fluorescent Multiplex Assay
    • RNAscope™ 2.5 LSx Reagent Kit-BROWN
    • RNAscope™ 2.5 LSx Reagent Kit-RED
    • BaseScope™ LS Reagent Kit – RED
    • miRNAscope LS Reagent Kit Red
    • RNAscope™ Plus smRNA-RNA LS Assay
    Roche DISCOVERY ULTRA system
    • Overview
    • RNAscope™ VS Universal HRP
    • RNAscope™ VS Universal AP
    • RNAscope™ VS Duplex Assay
    • BaseScope™ VS Reagent Kit – RED
    RNA-Protein Co-Detection Assay
    +
    • RNAscope HiPlex-IMC™ Co-Detection
    • Integrated Codetection Assay
    • Sequential RNA Protein Detection
    Software
    +
    • Overview
    • Aperio RNA ISH Algorithm
    • HALO® image analysis platform
    Controls & Accessories
    +
    • RNAscope™
    • BaseScope™
    • miRNAscope™
    • Accessories
    How to Order
    +
    • Ordering Instructions
    • What to Buy
  • Services +
    Professional Assay Services
    +
    • Our Services
    • Multiomic Services
    • Biomarker Assay Development
    • Cell & Gene Therapy Services
    • Clinical Assay Development
    • Tissue Bank & Sample Procurement
    • Image Analysis
    Benefits
    +
    • Your Benefits
    How to Order
    +
    • Ordering Process
    • Contact Services
  • Areas of Research +
    Most Popular
    +
    • COVID-19 Coronavirus
    • Single Cell Analysis
    • Whole-Mount
    • Anatomic Pathology Panels
    • Neuroscience
    • Inflammation
    • Gene Therapy/AAV
    • Stem Cell
    • Immuno-oncology
    • Liver Research
    • Cardiovascular & Skeletal Muscle Research
    Cell & Gene Therapy
    +
    • Gene Therapy
    • Gene Therapy/AAV
    • siRNA/ASO
    • Cell Therapy
    Cancer
    +
    • Breast Cancer
    • EGFRvIII Splice Variant
    • HPV Related Cancer
    • Immuno-oncology
    • Lung Cancer
    • PDx
    • Prostate Cancer
    • Point Mutation
    • CDR3 for TCR
    Viral
    +
    • COVID-19 Coronavirus
    • HIV & SIV
    • Infectious Disease
    • Zika Virus
    Pathways
    +
    • AKT
    • JAK STAT
    • WNT B-Catenin
    Neuroscience
    +
    Neuroscience
    • Neural Development
    • Neuronal Cell Types
    • Learning and Memory
    • G-protein-coupled Receptors & Ion Channels
    • Post-mortem Brain Tissue
    Other
    +
    • Circular RNA
    • Gene Fusions
    • HT Transcript Validation
    • Long Non-coding RNA
    • RNAseq Validation
    • Single Cell Analysis
    • Splice Variant
    • miRNA
    RNA & Protein
    +
    • Antibody Challenges
    • Dual ISH + IHC Methods
    • No Antibodies
    • RNA & Protein Analysis
    Customer Innovations
    +
    • Dual RNA+DNA ISH
    • Very old FFPE ISH
    • Wholemount ISH
    Animal Models
    +
    • Any Species
    • Mouse Model
    • Preclincal Safety
  • Technology +
    Overview
    +
    • How it Works
    • Data Image Gallery
    • Technology Video
    • Webinars
    RNA Detection
    +
    • Why RNA?
    • RNA ISH and IHC
    Pretreatment Options
    +
    • RNAscope™ Pretreatment
    • PretreatPro™
    Spotlights
    +
    • Researchers Spotlights
    • RNA & DNA
    • WISH
    • FFPE
    • Testimonials
    Publications, Guides & Posters
    +
    • Search publications
    • RNAscope™ Reference Guide
    • RNAscope™ Data Analysis Guide
    • Download RNAscope™ Posters
  • Support +
    Overview
    +
    • Get Started
    • How to Order
    • Distributors
    • Contact Support
    Troubleshooting
    +
    • Troubleshooting Guide
    • FAQs
    • User Manuals, SDS and Product Inserts
    • Documents and Downloads
    Imaging Resource
    +
    • Image Analysis
    • Image Registration Software
    • QuPath
    • HALO® image analysis platform
    Learn More
    +
    • Webinars
    • Training Videos
  • Partners +
    Partners
    +
    • Overview
    Partners Directory
    +
    Automation Partners
    • Leica Biosystem
    • Roche Diagnostics
    Workflow Partners
    • NanoString
    Software Partners
    • indica labs
    Become a Partner
    +
    • Learn How
  • Diagnostics +
    Diagnostics
    +
    • Diagnostics
    • Literature
    • Diagnostics ASR Probes
    • Diagnostics CE-IVD Probes
    • Diagnostics CE-IVD Detection
    • Companion Diagnostics
  • Image Calendar +
    Image Calendar
    +
    • Image Contest
    • Data Image Gallery
Search

Probes for PTEN

ACD can configure probes for the various manual and automated assays for PTEN for RNAscope Assay, or for Basescope Assay compatible for your species of interest.

  • Probes for PTEN (475)
  • Kits & Accessories (0)
  • Support & Documents (0)
  • Publications (32)
  • Image gallery (0)
Refine Probe List

Content for comparison

Species

  • Mouse (170) Apply Mouse filter
  • Human (130) Apply Human filter
  • Rat (38) Apply Rat filter
  • Monkey (32) Apply Monkey filter
  • Dog (32) Apply Dog filter
  • Macaca fascicularis fascicularis (32) Apply Macaca fascicularis fascicularis filter

Gene

  • PTEN (264) Apply PTEN filter
  • PINK1 (218) Apply PINK1 filter
  • TBD (5) Apply TBD filter
  • AR (2) Apply AR filter
  • ETV1 (2) Apply ETV1 filter
  • MYC (2) Apply MYC filter
  • Akt2 (2) Apply Akt2 filter
  • CD68 (1) Apply CD68 filter
  • CCL5 (1) Apply CCL5 filter
  • CD4 (1) Apply CD4 filter
  • CDKN1B (1) Apply CDKN1B filter
  • CXCL10 (1) Apply CXCL10 filter
  • ERG (1) Apply ERG filter
  • Dkk2 (1) Apply Dkk2 filter
  • PCA3 (1) Apply PCA3 filter
  • Tgfbr1 (1) Apply Tgfbr1 filter
  • PIK3CA (1) Apply PIK3CA filter
  • TERC (1) Apply TERC filter
  • TP63 (1) Apply TP63 filter
  • Bcl11b (1) Apply Bcl11b filter
  • Pik3cb (1) Apply Pik3cb filter
  • HOXB13 (1) Apply HOXB13 filter
  • SChLAP1 (1) Apply SChLAP1 filter
  • AKT1 (1) Apply AKT1 filter
  • AKT3 (1) Apply AKT3 filter
  • NFE2L2 (1) Apply NFE2L2 filter
  • NKX3-1 (1) Apply NKX3-1 filter
  • Map3k12 (1) Apply Map3k12 filter
  • p63 (1) Apply p63 filter
  • HPV (1) Apply HPV filter
  • LY6D (1) Apply LY6D filter
  • Erk5 (1) Apply Erk5 filter
  • Cd8 (1) Apply Cd8 filter
  • 5.8S rRNA (1) Apply 5.8S rRNA filter
  • Map3k13 (1) Apply Map3k13 filter
  • 45S (1) Apply 45S filter
  • IFITM4P (1) Apply IFITM4P filter
  • MiR-181a-5p (1) Apply MiR-181a-5p filter
  • cyclin D2 (1) Apply cyclin D2 filter
  • lncRNA HOTAIR (1) Apply lncRNA HOTAIR filter
  • RP11- 295G20.2 (1) Apply RP11- 295G20.2 filter

Platform

  • Manual Assay RNAscope HiPlex (156) Apply Manual Assay RNAscope HiPlex filter
  • Automated Assay for Leica Systems - RNAscope (51) Apply Automated Assay for Leica Systems - RNAscope filter
  • Manual Assay RNAscope (35) Apply Manual Assay RNAscope filter
  • Automated Assay for Ventana Systems - RNAscope (18) Apply Automated Assay for Ventana Systems - RNAscope filter
  • Automated Assay for Leica Systems - BaseScope (3) Apply Automated Assay for Leica Systems - BaseScope filter
  • Automated Assay for Ventana System - BaseScope (3) Apply Automated Assay for Ventana System - BaseScope filter
  • Manual Assay DNAscope (2) Apply Manual Assay DNAscope filter
  • Manual Assay miRNAscope (1) Apply Manual Assay miRNAscope filter

Channel

  • 1 (49) Apply 1 filter
  • 2 (44) Apply 2 filter
  • 3 (26) Apply 3 filter
  • 4 (26) Apply 4 filter
  • 6 (13) Apply 6 filter
  • 5 (4) Apply 5 filter

HiPlex Channel

  • T1 (26) Apply T1 filter
  • T10 (26) Apply T10 filter
  • T11 (26) Apply T11 filter
  • T12 (26) Apply T12 filter
  • T2 (25) Apply T2 filter
  • T3 (25) Apply T3 filter
  • T4 (25) Apply T4 filter
  • T5 (25) Apply T5 filter
  • T6 (25) Apply T6 filter
  • T7 (25) Apply T7 filter
  • T8 (25) Apply T8 filter
  • T9 (25) Apply T9 filter

Product

  • RNAscope 2.0 Assay (8) Apply RNAscope 2.0 Assay filter
  • RNAscope (5) Apply RNAscope filter
  • RNAscope Multiplex Fluorescent Assay (3) Apply RNAscope Multiplex Fluorescent Assay filter
  • RNAscope 2.5 HD Red assay (2) Apply RNAscope 2.5 HD Red assay filter
  • Basescope (1) Apply Basescope filter
  • miRNAscope (1) Apply miRNAscope filter
  • RNAscope 2.5 HD Reagent Kit - BROWN (1) Apply RNAscope 2.5 HD Reagent Kit - BROWN filter
  • RNAscope 2.5 VS Assay (1) Apply RNAscope 2.5 VS Assay filter
  • RNAscope Multiplex Fluorescent v2 (1) Apply RNAscope Multiplex Fluorescent v2 filter

Research area

  • Cancer (21) Apply Cancer filter
  • Neuroscience (4) Apply Neuroscience filter
  • lncRNA (3) Apply lncRNA filter
  • Aging (1) Apply Aging filter
  • Cancer stem cell (1) Apply Cancer stem cell filter
  • CGT (1) Apply CGT filter
  • Development (1) Apply Development filter
  • HPV (1) Apply HPV filter
  • Immunotherapy (1) Apply Immunotherapy filter
  • Memory (1) Apply Memory filter
  • Other (1) Apply Other filter
  • Racial Bias (1) Apply Racial Bias filter
  • Regeneration (1) Apply Regeneration filter
  • Spinal Cord injury (1) Apply Spinal Cord injury filter
  • Stem cell (1) Apply Stem cell filter

Product sub type

  • Target Probes (145) Apply Target Probes filter

Category

  • Publications (32) Apply Publications filter

Application

  • Cancer, Immunotherapy, Inflammation, Neuroscience, Stem Cell (213) Apply Cancer, Immunotherapy, Inflammation, Neuroscience, Stem Cell filter
  • Neuroscience (202) Apply Neuroscience filter
  • Cancer (5) Apply Cancer filter
  • Inflammation (5) Apply Inflammation filter
  • Stem Cell (5) Apply Stem Cell filter
  • Immunotherapy (5) Apply Immunotherapy filter
  • Cancer,Immunotherapy,Inflammation,Neuroscience,Stem Cell (4) Apply Cancer,Immunotherapy,Inflammation,Neuroscience,Stem Cell filter
A critical role for DLK and LZK in axonal repair in the mammalian spinal cord

The Journal of neuroscience : the official journal of the Society for Neuroscience

2022 Mar 31

Saikia, JM;Chavez-Martinez, CL;Kim, ND;Allibhoy, S;Kim, HJ;Simonyan, L;Smadi, S;Tsai, KM;Romaus-Sanjurjo, D;Jin, Y;Zheng, B;
PMID: 35361703 | DOI: 10.1523/JNEUROSCI.2495-21.2022

The limited ability for axonal repair after spinal cord injury underlies long-term functional impairment. DLK (MAP3K12) is an evolutionarily conserved MAP3K implicated in neuronal injury signaling from C. elegans to mammals. However, whether DLK or its close homologue LZK (MAP3K13) regulates axonal repair in the mammalian spinal cord remains unknown. Here we assess the role of endogenous DLK and LZK in the regeneration and compensatory sprouting of corticospinal tract (CST) axons in mice of both sexes with genetic analyses in a regeneration competent background provided by PTEN deletion. We found that inducible neuronal deletion of both DLK and LZK, but not either kinase alone, abolishes PTEN deletion-induced regeneration and sprouting of CST axons, and reduces naturally-occurring axon sprouting after injury. Thus, DLK/LZK-mediated injury signaling operates not only in injured neurons to regulate regeneration, but also unexpectedly in uninjured neurons to regulate sprouting. Deleting DLK and LZK does not interfere with PTEN/mTOR signaling, indicating that injury signaling and regenerative competence are independently controlled. Together with our previous study implicating LZK in astrocytic reactivity and scar formation, these data illustrate the multicellular function of this pair of MAP3Ks in both neurons and glia in the injury response of the mammalian spinal cord.SIGNIFICANCE STATEMENT:Functional recovery after spinal cord injury is limited due to a lack of axonal repair in the mammalian central nervous system (CNS). DLK and LZK are two closely related protein kinases that have emerged as regulators of neuronal responses to injury. However, their role in axon repair in the mammalian spinal cord has not been described. Here we show that DLK and LZK together play critical roles in axonal repair in the mammalian spinal cord, validating them as potential targets to promote repair and recovery after spinal cord injury. In addition to regulating axonal regeneration from injured pathways, they also regulate compensatory axonal growth from uninjured pathways, indicating a more pervasive role in CNS repair than originally anticipated.
Rapid Loss of RNA Detection by In Situ Hybridization in Stored Tissue Blocks and Preservation by Cold Storage of Unstained Slides

American Journal of Clinical Pathology

2017 Oct 09

Baena-Del Valle JA, Zheng Q, Hicks JL, Trock HFBJ, Morrissey C, Corey E, Cornish TC, Sfanos KS, De Marzo AM.
PMID: - | DOI: 10.1093/ajcp/aqx094

Abstract

Objectives

Recent commercialization of methods for in situ hybridization using Z-pair probe/branched DNA amplification has led to increasing adoption of this technology for interrogating RNA expression in formalin-fixed, paraffin-embedded (FFPE) tissues. Current practice for FFPE block storage is to maintain them at room temperature, often for many years.

Methods

To examine the effects of block storage time on FFPE tissues using a number of RNA in situ probes with the Advanced Cellular Diagnostic’s RNAscope assay.

Results

We report marked reductions in signals after 5 years and significant reductions often after 1 year. Furthermore, storing unstained slides cut from recent cases (<1 year old) at –20°C can preserve hybridization signals significantly better than storing the blocks at room temperature and cutting the slides fresh when needed.

Conclusions

We submit that the standard practice of storing FFPE tissue blocks at room temperature should be reevaluated to better preserve RNA for in situ hybridization.

Increased T cell infiltration elicited by Erk5 deletion in a Pten-deficient mouse model of prostate carcinogenesis.

Cancer Res.

2017 May 17

Loveridge C, Mui E, Patel R, Tan EH, Ahmad I, Welsh M, Galbraith J, Hedley A, Nixon C, Blyth K, Sansom OJ, Leung HY.
PMID: 28515147 | DOI: 10.1158/0008-5472.CAN-16-2565

Prostate cancer (PCa) does not appear to respond to immune checkpoint therapies where T cell infiltration may be a key limiting factor. Here we report evidence that ablating the growth regulatory kinase Erk5 can increase T cell infiltration in an established Pten-deficient mouse model of human PCa. Mice that were doubly mutant in prostate tissue for Pten and Erk5 (prostate DKO) exhibited a markedly increased median survival with reduced tumor size and proliferation compared to control Pten-mutant mice, the latter of which exhibited increased Erk5 mRNA expression. A comparative transcriptomic analysis revealed upregulation in prostate DKO mice of the chemokines Ccl5 and Cxcl10, two potent chemoattractants for T lymphocytes. Consistent with this effect, we observed a relative increase in a predominantly CD4+ T cell infiltrate in the prostate epithelial and stroma of tumors from DKO mice. Collectively, our results offer a preclinical proof of concept for ERK5 as a target to enhance T cell infiltrates in prostate cancer, with possible implications for leveraging immune therapy in this disease.

Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer.

Eur Urol.

2015 Dec 23

Mehra R, Udager AM, Ahearn TU, Cao X, Feng FY, Loda M, Petimar JS, Kantoff P, Mucci LA, Chinnaiyan AM.
PMID: 26724257 | DOI: 10.1016/j.eururo.2015.12.003.

The long noncoding RNA SChLAP1 is overexpressed in a subset of prostate cancers (PCa), and high SChLAP1 expression by in situ hybridization (ISH) independently predicts biochemical recurrence after radical prostatectomy. Importantly, although biochemical recurrence is a significant clinical outcome, it is not a validated surrogate for PCa-related mortality. Thus, we evaluated the association between SChLAP1 expression and development of lethal PCa in a large cohort of American men with PCa and long-term follow-up. SChLAP1 ISH was performed on tissue microarrays containing representative formalin-fixed, paraffin-embedded PCa tissue from all patients and scored using a semiquantitative method (ISH score range 0-400). Hazard ratios (HRs) for the association between SChLAP1 expression and time to development of lethal PCa were estimated using multivariable Cox regression analysis. Of the 937 patients evaluated, 89 (9.5%) had high SChLAP1 expression (ISH score ≥100), which in patients treated with radical prostatectomy was strongly associated with development of lethal PCa independent of age, Gleason score, pathologic stage, and PTEN status (HR 2.2, 95% confidence interval 1.1-4.1). These results suggest that SChLAP1 may be a useful tissue-based biomarker for identifying PCa patients at higher risk of lethal progression.

PATIENT SUMMARY:
We examined expression of the RNA molecule SChLAP1 in a large group of prostate cancer patients with long-term follow-up and found that patients with high SChLAP1 expression had a significantly higher chance of developing lethal disease.

DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation

Nat Med.

2018 Feb 12

Xiao Q, Wu J, Wang WJ, Chen S, Zheng Y, Yu X, Meeth K, Sahraei M, Bothwell ALM, Chen L, Bosenberg M, Chen J, Sexl V, Sun L, Li L, Tang W, Wu D.
PMID: 29431745 | DOI: 10.1038/nm.4496

Immunotherapy offers new options for cancer treatment, but efficacy varies across cancer types. Colorectal cancers (CRCs) are largely refractory to immune-checkpoint blockade, which suggests the presence of yet uncharacterized immune-suppressive mechanisms. Here we report that the loss of adenomatosis polyposis coli (APC) in intestinal tumor cells or of the tumor suppressor PTEN in melanoma cells upregulates the expression of Dickkopf-related protein 2 (DKK2), which, together with its receptor LRP5, provides an unconventional mechanism for tumor immune evasion. DKK2 secreted by tumor cells acts on cytotoxic lymphocytes, inhibiting STAT5 signaling by impeding STAT5 nuclear localization via LRP5, but independently of LRP6 and the Wnt-β-catenin pathway. Genetic or antibody-mediated ablation of DKK2 activates natural killer (NK) cells and CD8+ T cells in tumors, impedes tumor progression, and enhances the effects of PD-1 blockade. Thus, we have identified a previously unknown tumor immune-suppressive mechanism and immunotherapeutic targets particularly relevant for CRCs and a subset of melanomas.

Autocrine activation of MAPK signaling mediates intrinsic tolerance to androgen deprivation in LY6D prostate cancer cells

Cell reports

2023 Apr 13

Steiner, I;Flores-Tellez, TDNJ;Mevel, R;Ali, A;Wang, P;Schofield, P;Behan, C;Forsythe, N;Ashton, G;Taylor, C;Mills, IG;Oliveira, P;McDade, SS;Zaiss, DM;Choudhury, A;Lacaud, G;Baena, E;
PMID: 37060563 | DOI: 10.1016/j.celrep.2023.112377

The emergence of castration-resistant prostate cancer remains an area of unmet clinical need. We recently identified a subpopulation of normal prostate progenitor cells, characterized by an intrinsic resistance to androgen deprivation and expression of LY6D. We here demonstrate that conditional deletion of PTEN in the murine prostate epithelium causes an expansion of transformed LY6D+ progenitor cells without impairing stem cell properties. Transcriptomic analyses of LY6D+ luminal cells identified an autocrine positive feedback loop, based on the secretion of amphiregulin (AREG)-mediated activation of mitogen-activated protein kinase (MAPK) signaling, increasing cellular fitness and organoid formation. Pharmacological interference with this pathway overcomes the castration-resistant properties of LY6D+ cells with a suppression of organoid formation and loss of LY6D+ cells in vivo. Notably, LY6D+ tumor cells are enriched in high-grade and androgen-resistant prostate cancer, providing clinical evidence for their contribution to advanced disease. Our data indicate that early interference with MAPK inhibitors can prevent progression of castration-resistant prostate cancer.
MiR-181a-5p promotes neural stem cell proliferation and enhances the learning and memory of aged mice

Aging cell

2023 Feb 16

Sun, Q;Ma, L;Qiao, J;Wang, X;Li, J;Wang, Y;Tan, A;Ye, Z;Wu, Y;Xi, J;Kang, J;
PMID: 36797653 | DOI: 10.1111/acel.13794

Hippocampal neural stem cell (NSC) proliferation is known to decline with age, which is closely linked to learning and memory impairments. In the current study, we found that the expression level of miR-181a-5p was decreased in the hippocampal NSCs of aged mice and that exogenous overexpression of miR-181a-5p promoted NSC proliferation without affecting NSC differentiation into neurons and astrocytes. The mechanistic study revealed that phosphatase and tensin homolog (PTEN), a negative regulator of the AKT signaling pathway, was the target of miR-181a-5p and knockdown of PTEN could rescue the impairment of NSC proliferation caused by low miR-181a-5p levels. Moreover, overexpression of miR-181a-5p in the dentate gyrus enhanced the proliferation of NSCs and ameliorated learning and memory impairments in aged mice. Taken together, our findings indicated that miR-181a-5p played a functional role in NSC proliferation and aging-related, hippocampus-dependent learning and memory impairments.
Autocrine Activation of MAPK-Signaling Mediates Intrinsic Tolerance to Androgen Deprivation in LY6D Prostate Cancer Cells

SSRN Electronic Journal

2021 Nov 20

Steiner, I;Flores-Tellez, T;Mevel, R;Ali, A;Wang, P;Schofield, P;Forsythe, N;Ashton, G;Taylor, C;Mills, I;Oliveira, P;McDade, S;Zeiss, D;Choudhury, A;Lacaud, G;Baena, E;
| DOI: 10.2139/ssrn.3966640

The emergence of castration resistant prostate cancer is associated with a high mortality and remains an area of unmet clinical need. We recently identified a rare subpopulation of normal prostate progenitor cells, characterized by an intrinsic resistance to androgen-deprivation and marked by the expression of LY6D. We here describe the underlying mechanisms driving castration-resistance of LY6D+ luminal progenitors and their contribution to advanced prostate cancer. We demonstrate that conditional deletion of PTEN in the murine prostate epithelium causes an expansion of transformed LY6D+ progenitor cells in proximal and distal regions of the prostate without impairing stem cell properties. Transcriptomic analyses of LY6D+  luminal cells identified an autocrine positive feed-back loop, based on the secretion of amphiregulin (AREG), further increasing cellular fitness and organoid formation. Pharmacological interference with AREG-activated MAPK-signaling overcomes the castration-resistant properties of LY6D+ cells with a near complete suppression of organoid formation. Notably, LY6D+  tumor cells are enriched in prostate specimens from high-grade and androgen-resistant prostate cancer, providing clinical evidence for their contribution to advanced and also metastatic disease. Our data indicate that the prospective identification of LY6D+ cells could allow for an early interference with MAPK-inhibitors to prevent the emergence of castration-resistant prostate cancer.
Reprint of: Female Urethral Carcinoma: A contemporary review of the clinicopathologic features, with emphasis on the histo-anatomic landmarks and potential staging issues

Human pathology

2023 Mar 01

Lagarde-Lenon, MS;Aron, M;
PMID: 36894368 | DOI: 10.1016/j.humpath.2023.02.011

Primary female urethral carcinoma (PUC-F) accounts for less than 1% of all genitourinary malignancies and comprises a histologically diverse group of tumors that are usually associated with poor prognosis. The carcinomas documented at this site include adenocarcinoma (clear cell adenocarcinoma, columnar cell carcinoma, and Skene gland adenocarcinoma), urothelial carcinoma (UCa), and squamous cell carcinoma (SCC). Recent studies have shown adenocarcinomas to be the most common type of primary urethral carcinoma in females. As most of the urethral carcinomas morphologically resemble carcinomas arising from surrounding pelvic organs or metastases, these should be ruled out before making the diagnosis of PUC-F. These tumors are currently staged according to the 8th edition of the American Joint Committee on Cancer (AJCC) staging system. However, the AJCC system has limitations, including the staging of tumors involving the anterior wall of the urethra. Staging systems like the recently proposed histology-based female urethral carcinoma staging system (UCS) takes into account the unique histological landmarks of the female urethra to better stratify pT2 and pT3 tumors into prognostic groups, that correlate with clinical outcomes including recurrence rates, disease-specific survival and overall survival. Further larger multi-institutional cohorts are however required to validate the results of this staging system. There is very limited information regarding the molecular profiling of PUC-F. Thirty-one percent of clear cell adenocarcinomas have been reported to show PIK3CA alterations, whereas 15% of adenocarcinomas show PTEN mutations. Higher tumor mutational burden and PD-L1 staining have been reported in UCa and SCC. Although multimodality treatment is usually recommended in locally advanced and metastatic disease, the role of immunotherapy and targeted therapy is promising in select PUC-F cases.
Probing regenerative heterogeneity of corticospinal neurons with scRNA-Seq

Research square

2023 Feb 21

Kim, H;Saikia, J;Monte, K;Ha, E;Romaus-Sanjurjo, D;Sanchez, J;Moore, A;Hernaiz-Llorens, M;Chavez-Martinez, C;Agba, C;Li, H;Lusk, D;Cervantes, K;Zheng, B;
PMID: 36865182 | DOI: 10.21203/rs.3.rs-2588274/v1

The corticospinal tract (CST) is clinically important for the recovery of motor functions after spinal cord injury. Despite substantial progress in understanding the biology of axon regeneration in the central nervous system (CNS), our ability to promote CST regeneration remains limited. Even with molecular interventions, only a small proportion of CST axons regenerate1. Here we investigate this heterogeneity in the regenerative ability of corticospinal neurons following PTEN and SOCS3 deletion with patch-based single cell RNA sequencing (scRNA-Seq)2,3, which enables deep sequencing of rare regenerating neurons. Bioinformatic analyses highlighted the importance of antioxidant response and mitochondrial biogenesis along with protein translation. Conditional gene deletion validated a role for NFE2L2 (or NRF2), a master regulator of antioxidant response, in CST regeneration. Applying Garnett4, a supervised classification method, to our dataset gave rise to a Regenerating Classifier (RC), which, when applied to published scRNA-Seq data, generates cell type- and developmental stage-appropriate classifications. While embryonic brain, adult dorsal root ganglion and serotonergic neurons are classified as Regenerators, most neurons from adult brain and spinal cord are classified as Non-regenerators. Adult CNS neurons partially revert to a regenerative state soon after injury, which is accelerated by molecular interventions. Our data indicate the existence of universal transcriptomic signatures underlying the regenerative abilities of vastly different neuronal populations, and further illustrate that deep sequencing of only hundreds of phenotypically identified CST neurons has the power to reveal new insights into their regenerative biology.
Female Urethral Carcinoma: A contemporary review of the clinicopathologic features, with emphasis on the histo-anatomic landmarks and potential staging issues

Human pathology

2022 Aug 26

Lagarde-Lenon, MS;Aron, M;
PMID: 36037997 | DOI: 10.1016/j.humpath.2022.08.003

Primary female urethral carcinoma (PUC-F) accounts for less than 1% of all genitourinary malignancies and comprises a histologically diverse group of tumors that are usually associated with poor prognosis. The carcinomas documented at this site include adenocarcinoma (clear cell adenocarcinoma, columnar cell carcinoma and Skene gland adenocarcinoma), urothelial carcinoma (UCa) and squamous cell carcinoma (SCC). Recent studies have shown adenocarcinomas to be the most common type of primary urethral carcinoma in females. Since most of the urethral carcinomas morphologically resemble carcinomas arising from surrounding pelvic organs or metastases, these should be ruled out before making the diagnosis of PUC-F. These tumors are currently staged according to the 8th edition of the American Joint Committee on Cancer (AJCC) staging system. However, the AJCC system has limitations, including the staging of tumors involving the anterior wall of the urethra. Staging systems like the recently proposed histology based female urethral carcinoma staging system (UCS) takes into account the unique histological landmarks of the female urethra to better stratify pT2 and pT3 tumors into prognostic groups, that correlate with clinical outcomes including recurrence rates, disease-specific and overall survival. Further larger multi-institutional cohorts are however required to validate the results of this staging system. There is very limited information regarding the molecular profiling of PUC-F. 31% of clear cell adenocarcinomas have been reported to show PIK3CA alterations, while 15% of adenocarcinomas show PTEN mutations. Higher tumor mutational burden (TMB) and PD-L1 staining have been reported in UCa and SCC. Although multimodality treatment is usually recommended in locally advanced and metastatic disease, the role of immunotherapy and targeted therapy is promising in select PUC-F cases.
Axin2+ peribiliary glands in the periampullary region generate biliary epithelial stem cells that give rise to ampullary carcinoma

Gastroenterology

2021 Jan 16

Hayata, Y;Nakagawa, H;Kurosaki, S;Kawamura, S;Matsushita, Y;Hayakawa, Y;Suzuki, N;Hata, M;Tsuboi, M;Kinoshita, H;Miyabayashi, K;Mizutani, H;Nakagomi, R;Ikenoue, T;Hirata, Y;Arita, J;Hasegawa, K;Tateishi, K;Koike, K;
PMID: 33465373 | DOI: 10.1053/j.gastro.2021.01.028

Peribiliary glands (PBGs), clusters of epithelial cells residing in the submucosal compartment of extrahepatic bile ducts, have been suggested as biliary epithelial stem/progenitor cell niche; however, evidence to support this claim is limited due to a lack of PBG-specific markers. We therefore sought to identify PBG-specific markers to investigate the potential role of PBGs as stem/progenitor cell niches, as well as an origin of cancer. We examined the expression pattern of the Wnt target gene Axin2 in extrahepatic bile ducts. We then applied lineage tracing to investigate whether Axin2-expressing cells from PBGs contribute to biliary regeneration and carcinogenesis using Axin2-CreERT mice. Wnt signaling activation, marked by Axin2, was limited to PBGs located in the periampullary region. Lineage tracing revealed that Axin2-expressing periampullary PBG cells are capable of self-renewal and supplying new biliary epithelial cells (BECs) to the luminal surface. Additionally, the expression pattern of Axin2 and the mature ductal cell marker CK19 was mutually exclusive in periampullary region, and fate tracing of CK19+ luminal surface BECs revealed gradual replacement by CK19- cells, further supporting the continuous replenishment of new BECs from PBGs to the luminal surface. We also found that Wnt signal enhancer R-spondin3 secreted from Myh11-expressing stromal cells, corresponding to human sphincter of Oddi, maintained the periampullary Wnt signal-activating niche. Notably, introduction of PTEN deletion into Axin2+ PBG cells, but not CK19+ luminal surface BECs, induced ampullary carcinoma whose development was suppressed by Wnt inhibitor. A specific cell population receiving Wnt-activating signal in periampullary PBGs functions as biliary epithelial stem/progenitor cells and also cellular origin of ampullary carcinoma.

Pages

  • « first
  • ‹ previous
  • …
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • next ›
  • last »
X
Description
sense
Example: Hs-LAG3-sense
Standard probes for RNA detection are in antisense. Sense probe is reverse complent to the corresponding antisense probe.
Intron#
Example: Mm-Htt-intron2
Probe targets the indicated intron in the target gene, commonly used for pre-mRNA detection
Pool/Pan
Example: Hs-CD3-pool (Hs-CD3D, Hs-CD3E, Hs-CD3G)
A mixture of multiple probe sets targeting multiple genes or transcripts
No-XSp
Example: Hs-PDGFB-No-XMm
Does not cross detect with the species (Sp)
XSp
Example: Rn-Pde9a-XMm
designed to cross detect with the species (Sp)
O#
Example: Mm-Islr-O1
Alternative design targeting different regions of the same transcript or isoforms
CDS
Example: Hs-SLC31A-CDS
Probe targets the protein-coding sequence only
EnEmProbe targets exons n and m
En-EmProbe targets region from exon n to exon m
Retired Nomenclature
tvn
Example: Hs-LEPR-tv1
Designed to target transcript variant n
ORF
Example: Hs-ACVRL1-ORF
Probe targets open reading frame
UTR
Example: Hs-HTT-UTR-C3
Probe targets the untranslated region (non-protein-coding region) only
5UTR
Example: Hs-GNRHR-5UTR
Probe targets the 5' untranslated region only
3UTR
Example: Rn-Npy1r-3UTR
Probe targets the 3' untranslated region only
Pan
Example: Pool
A mixture of multiple probe sets targeting multiple genes or transcripts

Enabling research, drug development (CDx) and diagnostics

Contact Us
  • Toll-free in the US and Canada
  • +1877 576-3636
  • 
  • 
  • 
Company
  • Overview
  • Leadership
  • Careers
  • Distributors
  • Quality
  • News & Events
  • Webinars
  • Patents
Products
  • RNAscope or BaseScope
  • Target Probes
  • Controls
  • Manual assays
  • Automated Assays
  • Accessories
  • Software
  • How to Order
Research
  • Popular Applications
  • Cancer
  • Viral
  • Pathways
  • Neuroscience
  • Other Applications
  • RNA & Protein
  • Customer Innovations
  • Animal Models
Technology
  • Overview
  • RNA Detection
  • Spotlight Interviews
  • Publications & Guides
Assay Services
  • Our Services
  • Biomarker Assay Development
  • Cell & Gene Therapy Services
  • Clinical Assay Development
  • Tissue Bank & Sample Procurement
  • Image Analysis
  • Your Benefits
  • How to Order
Diagnostics
  • Diagnostics
  • Companion Diagnostics
Support
  • Getting started
  • Contact Support
  • Troubleshooting Guide
  • FAQs
  • Manuals, SDS & Inserts
  • Downloads
  • Webinars
  • Training Videos

Visit Bio-Techne and its other brands

  • bio-technie
  • protein
  • bio-spacific
  • rd
  • novus
  • tocris
© 2026 Advanced Cell Diagnostics, Inc.
  • Terms and Conditions of Sale
  • Privacy Policy
  • Cookie Settings
  • Security
  • Email Preferences
  • 
  • 
  • 

For Research Use Only. Not for diagnostic use. Refer to appropriate regulations. RNAscope is a registered trademark; and HybEZ, EZ-Batch and DNAscope are trademarks of Advanced Cell Diagnostics, Inc. in the United States and other countries. All rights reserved. ©2026 Advanced Cell Diagnostics, Inc.

 

Contact Us / Request a Quote
Download Manuals
Request a PAS Project Consultation
Order online at
bio-techne.com
OK
X
Contact Us

Complete one of the three forms below and we will get back to you.

For Quote Requests, please provide more details in the Contact Sales form below

  • Contact Sales
  • Contact Support
  • Contact Services
  • Offices

Advanced Cell Diagnostics

Our new headquarters office starting May 2016:

7707 Gateway Blvd.  
Newark, CA 94560
Toll Free: 1 (877) 576-3636
Phone: (510) 576-8800
Fax: (510) 576-8798

 

Bio-Techne

19 Barton Lane  
Abingdon Science Park
Abingdon
OX14 3NB
United Kingdom
Phone 2: +44 1235 529449
Fax: +44 1235 533420

 

Advanced Cell Diagnostics China

20F, Tower 3,
Raffles City Changning Office,
1193 Changning Road, Shanghai 200051

021-52293200
info.cn@bio-techne.com
Web: www.acdbio.com/cn

For general information: Info.ACD@bio-techne.com
For place an order: order.ACD@bio-techne.com
For product support: support.ACD@bio-techne.com
For career opportunities: hr.ACD@bio-techne.com

See Distributors
×

You have already Quick ordered an Item in your cart . If you want to add a new item , Quick ordered Item will be removed form your cart. Do You want to continue?

OK Cancel